Login / Signup

Deferasirox Derivatives: Ligands for the Lanthanide Series.

Daniel N MangelGabriel J JuarezStephanie H CarpenterAxel SteinbrueckVincent M LynchJian YangAdam C SedgwickAaron TondreauJonathan L Sessler
Published in: Journal of the American Chemical Society (2023)
Deferasirox is an FDA-approved iron chelator used in the treatment of iron toxicity. In this work, we report the use of several deferasirox derivatives as lanthanide chelators. Solid-state structural studies of three representative trivalent lanthanide cations, La(III), Eu(III), and Lu(III), revealed the formation of 2:2 complexes in the solid state. A 1:1 stoichiometry dominates in DMSO solution, with K a values of 472 ± 14, 477 ± 11, and 496 ± 15 M -1 being obtained in the case of these three cations, respectively. Under the conditions of competitive precipitation in the presence of triethylamine, high selectivity (up to 80%) for lutetium(III) was observed in competition with La(III), Ce(III), and Eu(III). Theoretical calculations provided support for the observed selective crystallization.
Keyphrases
  • solid state
  • single molecule
  • oxidative stress
  • metal organic framework
  • single cell
  • smoking cessation
  • replacement therapy